Literature DB >> 26833538

Longer procedural times are independently associated with symptomatic intracranial hemorrhage in patients with large vessel occlusion stroke undergoing thrombectomy.

Tareq Kass-Hout1, Omar Kass-Hout1,2, Chung-Huan Johnny Sun1,3, Taha A Kass-Hout4,5, Raul Nogueira1, Rishi Gupta1,6.   

Abstract

BACKGROUND: Time to reperfusion is an essential factor in determination of outcomes in acute ischemic stroke (AIS).
OBJECTIVE: To establish the effect of the procedural time on the clinical outcomes of patients with AIS.
METHODS: Data from all consecutive patients who underwent mechanical thrombectomy between September 2010 and July 2012 were analysed retrospectively. The variable of interest was procedural time (defined as time from groin puncture to final recanalization time). Outcome measures included the rates of symptomatic intracranial hemorrhage (sICH, defined as any parenchymal hematoma-eg, PH-1/PH-2), final infarct volume, 90-day mortality, and independent functional outcomes (modified Rankin Scale 0-2) at 90 days.
RESULTS: The cohort included 242 patients with a mean age of 65.5±14.2 and median baseline National Institutes of Health Stroke Scale score 20. 51% of the patients were female. The mean procedure time was significantly shorter in patients with a good outcome (86.7 vs 73.1 min, respectively, p=0.0228). Patients with SICH had significantly higher mean procedure time than patients without SICH (79.67 vs 104.5 min, respectively; p=0.0319), which remained significant when controlling for the previous factors (OR=0.974, 95% CI 0.957 to 0.991). No correlation was found between the volume of infarction and the procedure time (r=0.10996, p=0.0984). No association was seen between procedure time and 90-day mortality (77.8 vs 88.2 min in survivals vs deaths, respectively; p=0.0958).
CONCLUSIONS: Our data support an association between the risk of SICH and a longer procedure time, but no association between procedural times and the final infarction volume or long-term functional outcomes was found. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Hemorrhage; Stent; Stroke; Thrombectomy

Year:  2016        PMID: 26833538     DOI: 10.1136/neurintsurg-2015-012157

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  5 in total

1.  Impact of Modified TICI 3 versus Modified TICI 2b Reperfusion Score to Predict Good Outcome following Endovascular Therapy.

Authors:  C Dargazanli; A Consoli; M Barral; J Labreuche; H Redjem; G Ciccio; S Smajda; J P Desilles; G Taylor; C Preda; O Coskun; G Rodesch; M Piotin; R Blanc; B Lapergue
Journal:  AJNR Am J Neuroradiol       Date:  2016-11-03       Impact factor: 3.825

2.  Influence of procedure time on outcome and hemorrhagic transformation in stroke patients undergoing thrombectomy.

Authors:  Xianjun Huang; Qiankun Cai; Lulu Xiao; Mengmeng Gu; Yuanlu Liu; Zhiming Zhou; Wen Sun; Gelin Xu; Xinfeng Liu
Journal:  J Neurol       Date:  2019-07-03       Impact factor: 4.849

Review 3.  Efficacy and safety of direct aspiration versus stent-retriever for recanalization in acute cerebral infarction: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Chuan Qin; Ke Shang; Sha-Bei Xu; Wei Wang; Qiang Zhang; Dai-Shi Tian
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

4.  Early Neurological Deterioration Despite Recanalization in Basilar Artery Occlusion Treated by Endovascular Therapy.

Authors:  Xi Zhong; Xu Tong; Xuan Sun; Feng Gao; Dapeng Mo; Yilong Wang; Zhongrong Miao
Journal:  Front Neurol       Date:  2020-11-19       Impact factor: 4.003

5.  Clinical Significance of Hyperdense Lesions on Non-enhanced Brain CT Obtained Immediately after Arterial Revascularization in Acute Ischemic Stroke Patients.

Authors:  Changbin Wang; Zudong Yin; Xinyi Zhang; Xiumin Zhao
Journal:  Comput Math Methods Med       Date:  2021-09-03       Impact factor: 2.238

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.